A systematic review and network meta - analysis of pharmacological therapies used for patients with advanced Parkinson's disease 2014.pdf (493.28 kB)

A systematic review and network meta - analysis of pharmacological therapies used for patients with advanced Parkinson's disease (2014)

Download (493.28 kB)
poster
posted on 01.03.2020, 16:17 by Shijie Ren, Katy Cooper, James Cooper, Helen Smith, Soraya Shaikh

Parkinson’s disease affects about 110,000 people in the UK and 1.25 million people in Europe.1 Current options for management of advanced Parkinson’s disease include:

• Increased dose or frequency of immediate-release levodopa (IR LD)

• Supplemental controlled-release levodopa (CR LD)

• Adjunctive therapies with levodopa, including dopamine agonists, monoamine oxidase-B inhibitors (MAO-BIs), and catechol-O-methyl transferase inhibitors (COMTIs) A new modified release form of levodopa (IPX066) is in development.

History

Ethics

There is no personal data or any that requires ethical approval

Policy

The data complies with the institution and funders' policies on access and sharing

Sharing and access restrictions

The data can be shared openly

Data description

  • The file formats are open or commonly used

Methodology, headings and units

  • Headings and units are explained in the files

Licence

Exports

Logo branding

Licence

Exports